Giant Cell Arteritis

Disease State Hub

Commentary

Vasculitis

Plasma Exchange Does Not Provide Additional Benefit in Severe ANCA-Associated Vasculitis

04/18/2019

In this commentary, Vikas Majithia, MD, MPH, explains results of the PEXIVAS study and how they will impact the way rheumatologists treat patients with anti-neutrophil cytoplasm antibody-associated...

04/18/2019

Research Summaries

Treatment

Toxicity May Outweigh Treatment Benefit of IV Steroids in GCA

04/07/2021

Researchers reveal that the benefit of intravenous glucocorticoid treatment in patients with giant cell arteritis may not be significant enough to risk exposure to the drugs’ toxicity.

04/07/2021

Diagnosis

Vascular Ultrasound Deserves Wider Use in Diagnosing GCA in the US

03/25/2021

While already common practice in Europe, the use of vascular ultrasound to diagnose giant cell arteritis has been limited in the United States. New research aims to change that.

03/25/2021

Rheumatologic disorders

ACR and Vasculitis Foundation Preview the First Vasculitis Practice Guideline

11/12/2019

Sharon Chung, MD, lead investigator on the new practice guideline for vasculitis, discussed how the guideline will help rheumatologists manage classic systemic vasculitis conditions they may encounter in...

11/12/2019

Treatment

Steroid-Sparing Agents and Patients With LV-GCA

05/05/2011

Patients with large-vessel giant cell arteritis may see disease improvement when treated early with steroid-sparing agents, recent research reveals.

05/05/2011

Treatment

Research Tests Duration of Effect of Tocilizumab Among Patients With GCA

03/25/2011

Patients with giant cell arteritis see long-term effects after 1 year of treatment with tocilizumab

03/25/2011

April 2024

Current Issue

April 2024

Volume 64

Issue 4